Randomized trial evaluates multi-target CAR T re-infusion effectiveness in R/R B-NHL, suggesting new strategies to manage relapses.
Key Points
The study aims to assess the efficacy and safety of multi-target CAR T re-infusion strategies after prior CAR T therapy failure in patients with relapsed/refractory B-NHL.
Thirteen patients with R/R B-NHL post-CAR-T therapy received re-infusion targeting multiple antigens.
Targets included CD20, CD22, CD79b, and various CD19 constructs.
Responses assessed by standard lymphoma criteria and toxicity graded using established criteria.
Overall response rate (ORR) was 84.6% (11/13) with a complete response (CR) rate of 69.2% (9/13).
Progressive disease occurred in 23.1% (3/13).
Multi-target strategies showed clinical activity with manageable toxicity and no high-grade CRS/ICANS reported.